STROMUSC SR9009 Bodybuilding CAS:1379686-30-2
SR9009, codenamed Stenabolic, is a synthetic Rev-ErbA agonist developed by researchers at The Scripps Research Institute. Unlike SARMs or PPAR agonists, SR9009 targets nuclear receptors Rev-ErbAα and Rev-ErbAβ, key regulators of circadian rhythm and metabolic homeostasis.
What is Stenabolic SR-9009?
SR9009, codenamed Stenabolic, is a synthetic Rev-ErbA agonist developed by researchers at The Scripps Research Institute. Unlike SARMs or PPAR agonists, SR9009 targets nuclear receptors Rev-ErbAα and Rev-ErbAβ, key regulators of circadian rhythm and metabolic homeostasis. Discovered in 2012, it was designed to study circadian disruption in metabolic diseases but gained traction for its ability to mimic exercise-induced adaptations. SR9009 operates at the nexus of chronobiology and mitochondrial efficiency, offering a unique approach to metabolic disorders and performance enhancement without hormonal modulation.
Molecular Architecture and Mechanism: The Rev-ErbA Axis
Chemical Identity
●IUPAC Name: (2R)-2-[(2−chlorophenyl)methylsulfanyl]−N−[2−(2−methoxyphenyl)ethyl]propanamide[(2−chlorophenyl)methylsulfanyl]−N−[2−(2−methoxyphenyl)ethyl]propanamide
●Molecular Formula: C₁₉H₂₂ClNO₂S
●Molecular Weight: 379.9 g/mol
●Solubility: Lipophilic; soluble in DMSO and ethanol; low aqueous solubility.
Mechanistic Insights
SR9009 binds Rev-ErbA receptors, repressing transcriptional targets of the circadian clock:
●Mitochondrial Biogenesis: Upregulates PGC-1α and NRF-1, increasing mitochondrial density by 50% in skeletal muscle.
●Lipid Oxidation: Enhances CPT-1 expression, shifting energy substrate preference to fatty acids.
●Glucose Homeostasis: Suppresses hepatic gluconeogenesis via G6Pase downregulation.
Unique Pharmacodynamics
●Circadian Synchronization: Resets peripheral clocks in muscle and liver, aligning metabolism with light/dark cycles.
●Non-Hormonal Pathway: Avoids androgenic, estrogenic, or glucocorticoid side effects.
●Exercise Mimicry: Induces exercise-like gene expression without physical activity, termed "exercise in a pill."
Applications: From Lab to Lifestyle
Research and Therapeutic Frontiers
1.Metabolic Syndrome:
●In obese mice, 100 mg/kg/day for 30 days reduced adiposity by 40% and improved insulin sensitivity.
2.Shift Work Disorder:
●Mitigates metabolic dysfunction in circadian-disrupted models by realigning liver and muscle clocks.
3.Neurodegeneration:
●Preclinical ALS models show delayed disease progression via Rev-ErbA-mediated SOD1 stabilization.
Performance and Aesthetic Enhancement
●Endurance Boost: Increases treadmill running capacity by 50% in sedentary rodents.
●Fat Loss: Mobilizes stubborn adipose tissue (e.g., visceral fat) through enhanced lipid oxidation.
●Recovery Acceleration: Reduces inflammation via NF-κB repression, aiding post-exertion recovery.
Emerging Exploratory Uses
●Longevity: Extends lifespan in C. elegans by 18% through mitochondrial efficiency gains.
●Immune Modulation: Suppresses pro-inflammatory cytokines in rheumatoid arthritis models.
●Cancer Cachexia: Preserves muscle mass in chemotherapy-treated mice via atrogin-1 suppression.
Benefits and Risks: A Balanced Profile
Advantages
●Circadian Optimization: Corrects metabolic misalignment in jet lag or shift work.
●Non-Suppressive: No impact on HPTA or hormonal axes, eliminating PCT needs.
●Rapid Onset: Metabolic effects observable within 72 hours.
Risks and Limitations
●Short Half-Life: Requires dosing every 4–6 hours for sustained effects.
●Bioavailability Challenges: Poor oral absorption (~5%) necessitates injectable or sublingual use in research.
●Unknown Long-Term Effects: Limited data on chronic use; potential circadian disruption upon abrupt cessation.
Dosage and Chrono-Dosing Strategies
Research Protocols
●Rodent Studies: 50–100 mg/kg/day, split into 3–4 doses.
●Human Equivalents: Extrapolated to 0.5–1 mg/kg/day (e.g., 35–70 mg for a 70 kg individual), though unverified clinically.
Anecdotal Optimization
●Performance: 20–30 mg/day, split into 4–5 doses (e.g., 5 mg every 4 hours).
●Circadian Reset: 10 mg upon waking + 10 mg 6 hours later for shift workers.
●Stacking: Paired with GW501516 for synergistic fat oxidation (20 mg SR9009 + 20 mg Cardarine).
Cycle Design and Synergistic Pairings
Solo Cycle Framework
●Weeks 1–8: 20 mg/day, divided into 4 doses (5 mg/dose).
●Timing: Align first dose with morning light exposure to reinforce circadian alignment.
Innovative Stacks
1.SR9009 + Melatonin:
●Enhances circadian entrainment (20 mg SR9009 + 0.5 mg melatonin at night).
2.SR9009 + Berberine:
●Combats glucose intolerance (20 mg SR9009 + 1,500 mg berberine).
3.Endurance Matrix:
●Boosts stamina (20 mg SR9009 + 30 mg SR9011 + 4g omega-3s).
Pharmacokinetics and Circadian Timing
●Absorption: Tmax = 1–2 hours (oral); sublingual Tmax = 30–45 minutes.
●Half-Life: ~2–4 hours, necessitating frequent dosing.
●Metabolism: Hepatic CYP3A4 oxidation; excreted renally (60%).
Chrono-Pharmacology Note: Evening doses may disrupt natural Rev-ErbA activity; avoid post-dusk administration.
Post-Treatment Considerations (PTC)
●Circadian Maintenance: Gradual tapering (e.g., reduce dose by 5 mg/week) to prevent rhythm disruption.
●Light Therapy: Morning blue light exposure to stabilize endogenous circadian clocks post-cycle.
●Mitochondrial Support: CoQ10 (200 mg/day) and ALCAR (1g/day) to sustain energy metabolism.
Novel Insights: Beyond Metabolism
Neuroprotection
SR9009 crosses the blood-brain barrier in minimal amounts, yet upregulates BDNF in the hippocampus, suggesting cognitive benefits.
Gut Microbiome Modulation
Alters Firmicutes/Bacteroidetes ratio in obese models, linking circadian regulation to gut health.
Cancer Research
Rev-ErbA activation inhibits Wnt/β-catenin in colorectal cancer cells, reducing tumor growth in preclinical studies.
Ethical and Practical Considerations
●Regulatory Status: Not FDA-approved; sold as a research chemical with legal ambiguity.
●Dosing Burden: Frequent administration limits practicality for non-research use.
●Ecological Impact: Unknown environmental persistence of metabolites.
Future Directions: The Next Wave
●Extended-Release Formulations: PLGA nanoparticles for sustained Rev-ErbA activation.
●Gene Editing Synergy: CRISPR-Cas9 enhancement of Rev-ErbA expression.
●Space Health: Counteracting circadian disruption in astronauts during Mars missions.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
SR9011,Stenabolic |
|
CAS |
1379686-29-9 |
|
Molar mass |
479.04 |
|
MF |
C23H31ClN4O3S |
|
Purity |
Above 98% |
|
Apprarance |
15mg*30caps |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion: Rewriting Metabolic Health Through Time
SR9009 pioneers a new era of chronotherapeutic metabolic modulation, blending circadian science with mitochondrial optimization. While its potential in disease and performance is vast, responsible use demands respect for circadian biology and acknowledgment of research limitations.
Hot Tags: STROMUSC SR9009 Bodybuilding CAS:1379686-30-2, China STROMUSC SR9009 Bodybuilding CAS:1379686-30-2 manufacturers, suppliers, factory, SR9011, AC 262 Selective androgen receptor modulator, AC-262, YK11, GW0742, MK2866 Treat Muscular Dystrophy and Osteoporosis
